UNSPSC 51183104: Benfluorex hydrochloride

This classification denotes an anti-lipidemic agent and anorexiant with the molecular formula C19H20F3NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7O165XZ00, chemically known as phenethylamine, n-(2-hydroxyethyl)-alpha-methyl-m-trifluoromethyl-, benzoate but more generally known as benfluorex hydrochloride, which bears US NIH Compound Identifier 2318. European Medicines Agency schedules Benfluorex hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00701MIG.

Most nations, for tariff and trade purposes, schedule benfluorex hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, BENFLUOREX HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCC(C1)C(F)(F)F)NCCOC(=O)C2CCCCC2.CL.

UNSPSC 51183104 Benfluorex hydrochloride is a Commodity code encompassing branded and generic pharmaceutical active ingredients supplied to state and local health systems, correctional facilities, and related government entities. State and local governments procure under this code primarily through multistate cooperative purchasing agreements that aggregate demand across member jurisdictions, standardizing pricing, compliance requirements, and supply-chain relationships. The issuing bodies are typically state departments of administration or health, acting as administrators of cooperative purchasing consortia that serve participating states, counties, municipalities, and health agencies. Vendors supplying under this code must meet stringent regulatory and operational requirements, including FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, substantial insurance coverage (commercial general liability of $5,000,000 or greater, network security and privacy liability of $2,000,000 minimum), and contractual relationships with authorized pharmaceutical wholesalers operating chargeback systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (weighted at 75 percent of evaluation), with secondary weight on fixed pricing, EDI capability, administrative fee compliance, and format requirements. Awards are contingent on product availability by May 15, 2026, with contracts effective July 1, 2026, and a two-year initial term for new responders or alignment with incumbent expiration dates through June 30, 2028. No specific dollar value or budget range was disclosed in the solicitation materials.